About QIAGEN
QIAGEN news and updates
Element Biosciences partnered with QIAGEN, Inc. on Feb 22nd 22'.
Teaming up with Qiagen, Element will validate Qiagen's QiaSeq NGS library prep and target enrichment products on Aviti.
Jan 1, 2022 | genomeweb.comQiagen N.V partnered with Hamilton Company on Oct 10th 16'.
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of automated high-throughput solutions, developed in partnership with Hamilton Robotics, to serve the growing need for DNA fingerprinting of samples for human identity databases
Jan 1, 2016 | sys-con.comQiagen N.V recognized as top of the Diagnostics & Research industry
Qiagen NV ( QGEN ) is around the top of the Diagnostics & Research industry according to InvestorsObserver.
Jan 1, 2021 | investorsobserver.comQiagen N.V partners with Pathomics Health
Qiagen will collaborate with Pathomics Health to expand innovative infectious diseases solutions for both research and clinical diagnostics in Singapore.
Jan 1, 2022 | biospectrumasia.comQiagen N.V launches QIAstat-Dx test kit for the detection of SARS-CoV-2 coronavirus
For instance, in March 2020, Qiagen launched QIAstat-Dx test kit for the detection of SARS-CoV-2 coronavirus in Europe, and in April 2020, Altona Diagnostics launched CE-IVD marked RealStar SARS-CoV-2 RT-PCR Kit 1.0, an in vitro diagnostic test based on real-time PCR technology, for the qualitative detection of lineage B-beta coronavirus (lineage B-?
Jan 1, 2022 | yahoo.comQIAGEN, Inc. files suit against Bio-Rad Laboratories, Inc.
Qiagen has filed a lawsuit against Bio-Rad in a US federal court seeking a ruling that it has not infringed several Bio-Rad patents related to digital PCR technology.
Jan 1, 2022 | genomeweb.comAmerican Type Culture Collection Inc partnered with QIAGEN, Inc. on Apr 4th 22'.
ATCC, the world’s premier biological materials management and standards organization, today announced that it has entered into an agreement with QIAGEN, a recognized leader in bioinformatics solutions, to provide them with sequencing data from its collection of animal and human cell lines and biological materials.
Jan 1, 2022 | atcc.orgQIAGEN, Inc. launches EZ2 Connect
Hilden, Germany, and Germantown, Maryland, April 7, 2022 - QIAGEN today announced that EZ2 ® Connect, its next-generation instrument for sample preparation, has won the prestigious Red Dot award, one of the world's longest running and most important design competitions.
Jan 1, 2022 | marketscreener.comQIAGEN, Inc. launches QIAGEN Biomedical Knowledge Base
Redwood City, California, and Hilden, Germany, April 25, 2022 - QIAGEN Digital Insights, the bioinformatics business of QIAGEN, today announced the launch of QIAGEN Biomedical Knowledge Base in North America, Europe, Japan and Australia to support data science applications in pharmaceuticals and biotechnology that are becoming ever more important for drug discovery.
Jan 1, 2022 | marketscreener.comQIAGEN, Inc. partnered with Atilabiosystems on Jan 7th 22'.
Separately, Qiagen this week also said it is collaborating with Atila BioSystems on noninvasive prenatal testing to leverage Qiagen's digital PCR technology and sample preparation.
Jan 1, 2022 | 360dx.comQIAGEN, Inc. is developing SARS-CoV-2 tests
From the onset of the novel coronavirus outbreak, QIAGEN’s dedicated global teams have been working around the clock to ensure the availability of existing testing solutions and to develop new SARS-CoV-2 tests to address international testing needs.
Jan 1, 2022 | qiagen.comQIAGEN, Inc. launched QuantiFERON SARS-CoV-2 RUO solution on Dec 1st 20'.
For example, in December 2020, the QuantiFERON SARS-CoV-2 RUO solution was introduced by QIAGEN, a business that provides technologies and products for pre-analytical samples and related molecular test solutions.
Jan 1, 2022 | grandviewresearch.comQIAGEN, Inc. launches therascreen EGFR Plus RGQ PCR Kit
QIAGEN today announced the launch of the therascreen ® EGFR Plus RGQ PCR Kit, a new in-vitro diagnostic test for sensitive EGFR mutation analysis, detecting all currently known activating and resistance EGFR mutations.
Jan 1, 2022 | qiagen.comQIAGEN, Inc. acquires Blirt S.A
International biotech company QIAGEN has acquired over 96% of the shares of BLIRT.
Jan 1, 2022 | blirt.euQIAGEN, Inc. partnered with DiaSorin Group on Jun 1st 19'.
In June 2019, QIAGEN announced that the company is partnering up with DiaSorin for the expansion of their QuantiFERON collaboration.
Jan 1, 2022 | biospace.comQIAGEN, Inc. launches QIAstat-Dx Rise and enhancements
Qiagen ( NYSE: QGEN ) launched QIAstat-Dx Rise and enhancements to tests for the one-step molecular testing solution that provides results in about one hour.
Jan 1, 2022 | seekingalpha.comTCS partners with QIAGEN, Inc.
TCS’ team of cloud solution experts will work closely with QIAGEN to design, implement and manage a cloud-first model.
Jan 1, 2022 | tcs.comQIAGEN, Inc. is developing liquid biopsy-based companion diagnostic products on Jan 1st 21'.
For example, in 2021, QIAGEN and INOVIO Pharmaceuticals announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO's therapies.
Jan 1, 2022 | expertmarketresearch.comQIAGEN, Inc. launches series of enhancements for QIAcuity series of digital PCR instruments
Check them out: Qiagen announced a series of enhancements for its QIAcuity series of digital PCR (dPCR) instruments designed to drive greater use among customers, particularly those involved in the biopharma industry.
Jan 1, 2022 | centivis.comQIAGEN, Inc. launched QIAseq Targeted DNA Pro Panels and the QIAseq UPXome RNA Library Kit on Aug 9th 22'.
QIAGEN today announced the expansion of its next-generation sequencing (NGS) portfolio with the launch of QIAseq Targeted DNA Pro Panels and the QIAseq UPXome RNA Library Kit, both of which set new standards in preparing samples for determining their nucleic acid sequences.
Jan 1, 2022 | marketscreener.comQIAGEN, Inc. launches QIAstat-Dx Respiratory SARS-CoV-2 panel
When QIAGEN introduced the QIAstat-Dx Respiratory SARS-CoV-2 panel to distinguish between up to 23 viral and bacterial targets for common pathogens causing respiratory tract infections during the pandemic, the idea of syndromic testing demonstrated its significance.
Jan 1, 2022 | thehealthco.infoQIAGEN, Inc. launched QIAreach QuantiFERON-TB on Oct 1st 21'.
QIAGEN launched QIAreach QuantiFERON-TB (QIAreach QFT), a test featuring ultrasensitive digital detection built into a fully portable device, in October 2021.
Jan 1, 2022 | qiagen.comQIAGEN, Inc. is developing companion diagnostic for Neuron23's LRRK2 inhibitor for Parkinson's disease on Sep 14th 22'.
Neuron23™ Inc., an early stage bio technolog y company focused on developing precision medicine s for genetically defined neurological and immunological diseases, and QIAGEN ( NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to develop a companion diagnostic for Neuron23's LRRK2 inhibitor for Parkinson's disease.
Sep 13, 2022 | cmocro.comQIAGEN, Inc. is developing LRRK2 inhibitor
QIAGEN and Neuron23 have announced a collaboration to develop a companion diagnostic for the biotech’s LRRK2 inhibitor, which is currently in the late stages of preclinical development for Parkinson’s disease.
Sep 15, 2022 | insideprecisionmedicine.comQIAGEN, Inc. launched QIAseq Expanded Carrier Screening Panel on Jun 1st 19'.
For instance, in June 2019, QIAGEN, a German provider of sample and assay technologies for molecular diagnostics, launched QIAseq Expanded Carrier Screening Panel.
Sep 20, 2022 | einnews.comQIAGEN, Inc. launches QiaStat-Dx Viral Vesicular Panel
Qiagen has launched the QiaStat-Dx Viral Vesicular Panel.
Aug 19, 2022 | genomeweb.comBio-Rad Laboratories, Inc. will merge with QIAGEN, Inc. on Oct 17th 22'.
Bio-Rad Laboratories is talks to merge with Qiagen in a deal that may be valued at more than $10 billion, The Wall Street Journal reported on Monday, citing people familiar with the matter.
Oct 10, 2022 | medtechdive.comQIAGEN, Inc. is developing NGS assay to detect a 50 single nucleotide polymorphism
Specifically, Qiagen will develop and validate an NGS assay to detect a 50 single nucleotide polymorphism (SNP) biomarker discovered by Neuron23 to predict how Parkinson’s patients will respond to LRRK2 inhibitor treatment.
Oct 2, 2022 | g2intelligence.comThermo Fisher Scientific acquires QIAGEN, Inc. for $10B
Thermo Fisher once planned to acquire Qiagen for about $10 billion.
Oct 11, 2022 | investors.comQIAGEN, Inc. launches monkeypox test for NeuMoDx automated PCR platform
QIAGEN has launched a monkeypox (MPXV) test for its NeuMoDx automated PCR platform to boost surveillance and research into the current outbreak in non-endemic regions.
Nov 21, 2022 | mpo-mag.comQIAGEN, Inc. launches NeuMoDx MPXV Test Strip
Qiagen has launched the NeuMoDx MPXV Test Strip, a research-use-only multiplex assay that identifies both clades of monkeypox.
Dec 1, 2022 | genomeweb.comQIAGEN, Inc. launched EpiTect Hi-C kit.This on Jan 1st 20'.
For instance, in 2020, Qiagen, a German provider of sample and assay technologies, declared the licensed agreement for Hi-C Sequencing technology, and launched the EpiTect Hi-C kit.This is a single box solution that need less than 250,000 mammalian cells to produce sequence-ready libraries.
Dec 14, 2022 | yahoo.comQIAGEN, Inc. launched Non-invasive Prenatal Testing solutions on Jan 1st 17'.
QIAGEN collaborated with Atila BioSystems to offer Non-invasive Prenatal Testing (NIPT) solutions to QIAGEN’s dPCR franchise.
Sep 11, 2022 | fortunebusinessinsights.comQIAGEN, Inc. launched QIAscreen HPV PCR Test on Jan 1st 19'.
For instance, in January 2019, Qiagen, a worldwide provider of molecular sample and assay technologies, launched its QIAscreen HPV PCR Test, for detection of 15 recognized high risk genotypes of human papillomavirus which is a CE-marked in vitro molecular diagnostic test.
Dec 27, 2022 | medgadget.com